We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

This study has been terminated.
(The study was terminated after a pre-planned futility analyses showed an insufficient level of efficacy in the study population to warrant continuation.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01621243
First Posted: June 18, 2012
Last Update Posted: January 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Momenta Pharmaceuticals, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2016
  Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)